Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) EBIT Margin (2023 - 2025)

Historic EBIT Margin for Immunocore Holdings (IMCR) over the last 5 years, with Q3 2025 value amounting to 6.92%.

  • Immunocore Holdings' EBIT Margin rose 36800.0% to 6.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.88%, marking a year-over-year increase of 110800.0%. This contributed to the annual value of 22.71% for FY2024, which is 12000.0% up from last year.
  • Per Immunocore Holdings' latest filing, its EBIT Margin stood at 6.92% for Q3 2025, which was up 36800.0% from 15.18% recorded in Q2 2025.
  • In the past 5 years, Immunocore Holdings' EBIT Margin ranged from a high of 3.85% in Q1 2025 and a low of 573.78% during Q4 2021
  • Moreover, its 5-year median value for EBIT Margin was 23.08% (2024), whereas its average is 110.37%.
  • In the last 5 years, Immunocore Holdings' EBIT Margin skyrocketed by 5259200bps in 2022 and then crashed by -106900bps in 2024.
  • Over the past 5 years, Immunocore Holdings' EBIT Margin (Quarter) stood at 573.78% in 2021, then surged by 92bps to 47.86% in 2022, then surged by 49bps to 24.3% in 2023, then rose by 5bps to 23.14% in 2024, then skyrocketed by 70bps to 6.92% in 2025.
  • Its EBIT Margin stands at 6.92% for Q3 2025, versus 15.18% for Q2 2025 and 3.85% for Q1 2025.